Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
|Podcasts|September 14, 2020
Oncology Peer Review On-The-Go: 1-on-1 with Dr. Michael Randell: New ACS Guidelines for Cervical Cancer
Author(s)Matthew Fowler
The latest episode of Oncology Peer Review On-The-Go sits down with Michael D. Randell, MD, FACOG, to discuss the latest updates to cervical cancer screening guidelines by the American Cancer Society.
Advertisement
In this week’s episode of “Oncology Peer Review On-The-Go,” CancerNetworkspeaks with Michael D. Randell, MD, FACOG, of OBGYN Atlanta, to learn more about the new cervical cancer screening guidelines released by the American Cancer Society. In the interview, Randell expresses his concerns with the updated guidelines, and details what he recommends to patients.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Advertisement
Related to this article
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5